NANOSMART® Pharmaceuticals, Inc.

Executive Summary
September 2017

NanoSmart® Pharmaceuticals has developed a novel drug delivery platform that can target many types of cancer and other disorders. The key to NanoSmart's platform technology is a patented, human-derived, antinuclear antibody (ANA) that targets areas of necrosis present in a majority of solid tumors. A drug is placed within a lipid nanoparticle that is coated with NanoSmart's antibody. The drug is thereby delivered directly to diseased tissue while protecting normal, healthy tissues from the drug's toxic effects. The result is safer and more effective drugs. ***NanoSmart's patented antibody enables development of a virtually unlimited number of novel, targeted drug formulations at a fraction of the cost/time typically associated with new drug development.***



NanoSmart's Targeted Nanoparticles (image above). The nanoparticle encapsulates an anti-cancer agent and is coated with NanoSmart's patented antibodies. The drug formulation is administered intravenously and travels in the blood to the tumor sites. Once the targeted nanoparticles reach areas of necrosis within and around tumors, they bind there and slowly release the anti-cancer agent, eliminating the tumor while protecting healthy cells.

DELIVERS MEDICINE TO SOLID TUMORS

When a solid tumor grows uncontrollably, parts of the tumor are cut off from the blood supply and die, leaving pockets of necrosis (massive cell death) within the tumor. NanoSmart's targeted nanoparticles travel to the tumor site, bind to necrotic areas, and release the cancer drug at the tumor.

TARGETS NECROSIS NON-TUMOR SPECIFIC

NanoSmart's proprietary drug delivery systems are true platform technologies because necrosis is found in many different types of cancer. The targeted nanoparticles can be used for all solid tumor cancers like breast, lung, and prostate cancers; and rare pediatric cancers like Ewing's Sarcoma.

IMPROVES SAFETY & EFFICACY OF EXISTING DRUGS

Healthy tissues do not have areas of necrosis and are not targeted. Therefore, the nanoparticle that encloses the API protects healthy tissues while traveling to its target, and then slowly releases the drug over time. The end-result is a superior safety and efficacy profile for any drug that is adapted to our system.

Market Overview

It is estimated that 15,780 children (less than 1% of new cancer cases) were diagnosed with cancer in 2014. Despite being the leading cause of death in children, pediatric cancers continue to be underserved. NanoSmart's proprietary antibody enables it to focus its initial product development efforts on the most needy populations while establishing the therapeutic potential of its platform techologies for expanded indications.

Development Strategy

NanoSmart is currently focused on developing ANA-targeted nanoparticles containing existing, well-understood cancer drugs. This includes production and characterization of the nanoparticles, nonclinical safety testing, and preparation of Investigational New Drug (IND) applications. Lead candidates will be initially indicated for pediatric cancer.

Milestones

Multiple orphan drug designations: NanoSmart has received FDA orphan drug designations for Ewing's sarcoma (ES) for two of its lead candidates: ANA-conjugated liposomal doxorubicin and an ANA-conjugated dactinomycin nanoemulsion. This designation qualifies NanoSmart for certain incentives including application fee waivers, tax credits, access to grant funding, and market exclusivity upon approval.

IP secured: Patents for "autoantibodies utilized as carrier agents for pharmaceutical compounds used in tumor imaging and cancer treatment" have been granted in the US (US 7,799,327) and internationally (EP 1706145 B1). Additional IP has been licensed and filed. NanoSmart also relies on trade secrets to further secure its IP base.

Targeting antibody completed and preliminary formulations developed: Targeted nanoparticle formulations of dactinomycin, etoposide, doxorubicin, and docetaxel are currently in nonclinical development.

Licensing agreements: NanoSmart holds an exclusive option to license use of acid ceramidase (AC) inhibitors for cancer from UC Irvine. AC inhibitors are chemosensitizers that have the potential to synergistically combine with other chemotherapeutic agents in NanoSmart's multi-drug formulations. Additionally, NanoSmart has licensed a unique diagnostic marker from CHLA to develop a novel *in vitro* diagnostic test for Ewings sarcoma.

Research collaborations: NanoSmart has performed preliminary preclinical safety/efficacy studies at Children's Hospital Los Angeles (CHLA) under Dr. Timothy Triche, Director of the Center for Personalized Medicine, Saban Research Institute. Studies in other pediatric sarcomas will be performed under Dr. Noah Federman, Director of the Pediatric Bone and Soft Tissue Sarcoma Program at UCLA and Asst. Professor of Pediatrics, Hematology/Oncology at Mattel Children's Hospital at UCLA.

Pipeline



Regulatory Strategy

NanoSmart will seek additional orphan drug status for pediatric cancer indications. An Investigational New Drug (IND) application for phase I/II clinical studies is planned for submission following completion of nonclinical testing.

Exit Strategies

Licensing - Proprietary drug delivery platform enables licensing opportunities with multiple pharma companies. Avg. licensing/acquisition total deal values from $100 Million to over $1 Billion.

Direct Commercialization - NanoSmart will seek to efficiently commercialize products for multiple pediatric cancer indications with future potential to expand to larger cancer populations.

IPO - An IPO will be considered if additional funds are required for growth or if significant valuation is achieved.

M&A - Prime target for M&A by big pharma companies seeking to replenish product pipelines and/or extend patent life and improve the safety and efficacy of existing drugs.

NanoSmart Competitive Advantages

NanoSmart	Industry
ANA targets all solid tumors, enabling multiple platform technologies.	Therapeutic target is typically genome-specific, allowing for only a single indication.
Uses a non-immunogenic human-derived antibody.	Uses monoclonal antibodies.
Formulations have long-term stability in injectible form, w/ timed release when injected.	Formulations must be lyophilized and used immediately after complex reconstitution steps.
Utilizes expedited regulatory pathways (e.g. Orphan Drug Designation, Fast Track Designation, Priority Review).	Utilizes traditional New Drug Application (NDA) pathway.

Competition

NanoSmart's competition includes existing pharma companies with cancer drugs that use tumor-targeting monoclonal antibodies, such as: Roche's Avastin®, Rituxan®, and Herceptin®; Lily & Bristol Myers Squibb / Merck's Erbitux®; and Amgen's Vectibux®. Also, development stage companies such as: BIND Therapeutics' BIND-014 nanoparticle, Peregrine Pharmaceutical's Cotara®, and Merrimack Pharmaceutical's MM-398.

Management

Henry Smith, Ph.D., CEO & Chairman; Expert in tumor immunology; 40+ years in the healthcare industry; Founded and managed several biotech and medical reference labs. PhD in Medical Immunology Univ. Leeds School of Medicine, England.

James Smith, Ph.D., President; 15+ years experience in regulatory affairs and development of novel technologies. Guided numerous medical technologies from concept through commercialization. PhD in Pharmacology and Toxicology, UC Irvine.

Daniel Thiel, VP of Business Development; 10+ years of experience in business development, corporate finance, investor relations, and marketing for early-stage biotech companies.

Matthew Rossi, MBA, CFO; 24+ years of experience in financial planning/analysis, budgeting/forecasting, mergers/acquisitions, modeling, strategic planning, corporate development, and accounting. B.A. (economics) and MBA (finance), University of Connecticut.

Advisory Board

Sarath Kanekal, RAC, DVM, Ph.D., DABT - Expert in advancing drugs from development through NDA. 30+ IND/NDA/BLA's, including 15+ cancer drugs with extraordinary success rate.

Vincent F. Simmon, Ph.D. - 30+ years in business development, corporate leadership, and product development. CEO or COO of numerous public and private pharmaceutical companies.

Reg Wilson - 30+ years in financial industry. Registered investment advisor providing wealth management strategies for both businesses and individuals.

Guru Betageri, Ph.D. - Assistant dean and professor of pharmaceutical sciences at Western University of Health Sciences. Well-published expert in liposome drug delivery systems.

H. Vernon Roohk, Ph.D. - 30+ years as biomedical and bioengineering researcher and consultant with extensive experience in management of both private and university laboratories.

Dan Thiel, VP of Business Development
Email: dthiel@nanosmartpharma.com
Direct: 310-951-3282

NanoSmart Pharmaceuticals, Inc.
27071 Cabot Road, Suite 104
Laguna Hills, CA 92653

Phone: 949-305-2020
Fax: 949-340-7141
www.NanoSmartPharma.com